9 February 2026

Innovative Treatment Strategies for Inflammatory Skin Diseases Explored

Emerging Therapeutic Strategies in Dermatology: Insights from the South Beach Symposium 2026

During an insightful discussion at the South Beach Symposium 2026, Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine and editor-in-chief of Dermatology Times, shared his thoughts on the latest therapeutic advancements in managing inflammatory skin conditions. His primary focus was on atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS).

Dr. Bunick’s observations indicate a significant shift in the field of dermatology towards greater biological precision, aiming for improved treatment outcomes for patients. He emphasized that atopic dermatitis is a complex, biologically diverse condition influenced by multiple inflammatory pathways rather than a singular cause.

“In AD, we know that the underlying pathophysiology is very heterogeneous, meaning there are multiple cytokines that drive atopic dermatitis,” stated Bunick. While current biologics that primarily target TH2 cytokines have made a notable impact in patient care, they do not fully encompass the diverse biological factors that contribute to the disease in all individuals.

Advancements in Biologics

In response to this challenge, researchers are developing bispecific and trispecific biologics that aim to more comprehensively address various inflammatory pathways. The ultimate goal of these innovations is to achieve deeper skin clearance, as well as enhance control over itch and pain, thus providing patients with significantly improved quality of life.

The Role of Selective Intracellular Signaling Inhibitors

Beyond the realm of biologics, Dr. Bunick stressed the increasing significance of selective intracellular signaling inhibitors, particularly those that target tyrosine kinase 2 (TYK2). Although TYK2 belongs to the family of Janus kinase (JAK) enzymes, its inhibition operates through a different mechanism compared to conventional JAK inhibitors.

“What truly sets TYK2 inhibitors apart from traditional JAK inhibitors is the specific targets within the JAK enzyme family,” Bunick explained. Unlike JAK inhibitors that bind to the kinase domain, TYK2 inhibitors interact with the regulatory or allosteric domain, which leads to enhanced selectivity and reduced overlap with other JAK enzymes.

Clinical Efficacy and Safety of TYK2 Inhibitors

The first-generation TYK2 inhibitor, deucravacitinib, has already shown sustained efficacy and a reassuring safety profile in treating psoriasis, backed by over four years of clinical data. Dr. Bunick reported that this treatment has not indicated any increased risk for malignancy, major adverse cardiovascular events, or venous thromboembolism when compared to background rates in the general population.

Looking ahead, next-generation TYK2 inhibitors, such as zasocitinib and envudeucitinib, are being developed with even greater selectivity. Phase 3 data for zasocitinib is anticipated soon, although some manageable adverse events, such as acneiform eruptions and folliculitis, have been observed.

Genetic Insights Supporting TYK2 Inhibition

Dr. Bunick also pointed to genetic evidence that supports TYK2 as a promising therapeutic target. He highlighted naturally occurring human variants that exhibit reduced TYK2 function, which correlate with lower incidences of immune-mediated diseases, underscoring the potential safety of targeting this pathway.

Future Directions in Dermatological Research

Looking to the future, Dr. Bunick expressed enthusiasm for the application of JAK and TYK2 inhibitors in areas that currently lack effective treatments, including vitiligo, alopecia areata, dermatomyositis, and hidradenitis suppurativa. In particular, he called for elevated clinical trial benchmarks in HS, stating, “I really want to see the endpoint bar being raised,” and challenged the possibility of future therapies achieving results that extend beyond modest response rates to deliver truly transformative outcomes.

In summary, these advancements highlight the evolving landscape of therapeutic options in dermatology, characterized by increasingly specific pathways, enhanced safety profiles, and elevated expectations for long-term disease management.